Following this initial phase, maintenance therapy is frequently recommended to sustain the immune response. By triggering a localized inflammatory immune response, the therapy alerts the body’s defenses to target any remaining cancer cells left after the initial transurethral resection.
BCG Versus Other Intravesical Options: Weighing the Benefits and Risks
More serious complications, although rare, can include systemic infection or bladder scarring. These cells release cytokines and other substances that create an environment hostile to cancer cells, thereby destroying them and inhibiting the growth of new tumors.
This maintenance phase can extend for one to three years, involving instillations at longer intervals, such as once a week for three weeks every three months. Monitoring Efficacy and Long-Term Outcomes Regular follow-up is essential to determine whether the therapy is controlling the disease.
BCG Versus Other Intravesical Options: Weighing Effectiveness and Suitability
The standard course begins with a series of weekly instillations, often referred to as the induction course, which may last for six weeks. Long-term data indicate that successful BCG therapy can preserve bladder function, allowing patients to avoid more radical procedures like cystectomy.
More About Intravesical therapy bcg
Looking at Intravesical therapy bcg from another angle can help expand the discussion and give readers a second clear paragraph under the same section.
More perspective on Intravesical therapy bcg can make the topic easier to follow by connecting earlier points with a few simple takeaways.
